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Summary We determined the amount of tamoxifen, N-desmethyltamoxifen (metabolite X), N-
desdimethyltamoxifen (metabolite Z), and hydroxylated metabolites (Y, B, BX) in brain metastases from
breast cancer and in the surrounding brain tissues. Specimens were collected from three breast cancer patients
who received tamoxifen for 7-180 days and with the last dose taken within 28 h before surgical removal ofthe
tumour. The concentrations of tamoxifen and its metabolites were up to 46-fold higher in the brain metastatic
tumour and brain tissue than in serum. Metabolite X was the most abundant species followed by tamoxifen
and metabolite Z. Small but significant amounts of the hydroxylated metabolites, trans-1(4-p-
hydroxyethoxyphenyl)-1,2-diphenylbut-1-ene (metabolite Y), 4-hydroxytamoxifen (metabolite B) and 4-
hydroxy-N-desmethyltamoxifen (metabolite BX) were detected in most specimens. The ratios between the
concentrations of tamoxifen and various metabolites were similar in tumour, brain and serum. This is the first
report on the distribution of tamoxifen and metabolites into human brain and brain tumour, and the data
form a basis for further investigation into the therapeutic effects of tamoxifen on brain metastases from breast
cancer.
Brain metastases have been detected at autopsy in about
20% of the patients dying from advanced breast cancer
(Tsukada et al., 1983). Brain metastases occur most fre-
quently in patients below 60 years of age (DiStefano et al.,
1979; Sparrow et al., 1981; Zimm et al., 1981), and are the
cause of considerable morbidity.
Survival after the diagnosis of brain metastases is usually
very poor regardless ofthe nature of the primary tumour (Le
Chevalier et al., 1985). However, in patients with solitary
metastases from the breast cancer, little evidence of disease
elsewhere, and long disease-free intervals, surgical extirpation
is occasionally quite successful (Carey et al., 1981; Lang et
al., 1964).
In general, brain metastases are treated with corti-
costeroids and/or radiotherapy (Vlasveld et al., 1990), as the
central nervous system has been considered as a pharma-
cological sanctuary for most systemically delivered chemo-
therapeutic agents (Dauplat et al., 1987; Greig et al., 1987).
Response of cerebral metastases from breast cancer to endo-
crine drugs including tamoxifen, has been reported in a few
patients (Carey et al., 1981; Colomer et al., 1988; Grisoli et
al., 1981; Hansen et al., 1986).
Tamoxifen is a non-steroidal oestrogen antagonist used in
the first-line endocrine treatment of breast cancer. Tamoxifen
undergoes extensive hepatic metabolism. In man metabolites
formed by N-demethylation, i.e. metabolites X and Z, are the
main circulating species (Figure 1). Significant amounts of
hydroxylated metabolites including metabolite Y, B (Jordan
et al., 1984), and BX (Lien et al., 1988) have also been
demonstrated in serum.
Obviously, the ability of tamoxifen or its metabolites to
cross the blood brain barrier and to distribute into brain
metastases are prerequisites for therapeutic effect. Noguchi et
al. (1988) did not find tamoxifen in the cerebrospinal fluid
(CSF) of tamoxifen treated patients. We recently detected
small amounts of tamoxifen and N-desmethyltamoxifen in
human CSF (Lien et al., 1989), and Wilking et al. (1982)
found distribution of radioactivity into brain from mice
injected with '4C tamoxifen.
There is no report on the presence of tamoxifen or its
metabolites in brain tissue or brain metastases from humans.
In the present paper we report on the distribution of these
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R2Q X
R, QCH2-CH3
Identity Abbreviation R, R2
Tamoxifen Tam H CH3-NCH2CH2O CH3~ C2
4-Hydroxytamoxifen Metabolite B HO CH3-NCH2CH2O
4-Hydroxy-N-desmethyl- Metabolite BX HO CH3-NCH2CH2O
tamoxifen H
N-Desmethyltamoxifen Metabolite X H CH3.. NCH2CH20
N-Desdimethyltamoxifen Metabolite Z H H XNCH2CH20
Primary alcohol Metabolite Y H HO-CH2CH20
Figure 1 Structural formulas of tamoxifen and five metabolites.
compounds into normal brain tissue and into brain meta-
stases from three breast cancer patients.
Materials and methods
Patients
Patient AN was a woman who, in 1978, at the age of 36
years, underwent a mastectomy followed by surgical castra-
tion for a breast cancer. In 1981 a solitary cerebral metastasis
was surgically removed. She received whole brain radiation
therapy with a cumulative dose of 5,000 cGy (200 cGy frac-
tions over a period of 5 weeks). In 1986 she was admitted
because of a cerebellar metastasis. This tumour completely
disappeared following treatment with adriamycin 20 mg
weekly for 23 weeks after which the patient refused further
chemotherapy. The cerebellar tumour reappeared in 1988 and
was surgically removed. Microscopic examination of the
tumour tissue revealed a breast cancer metastasis.
Patient BO was a woman who, in 1986 at an age of 69
years, had a mastectomy for a breast cancer. Fifteen months
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after mastectomy a cerebellar tumour was surgically
removed. Pathological examination revealed a breast cancer
metastasis.
Patient RA was a woman who, in 1983 at an age of 49
years, underwent a mastectomy for a breast cancer. One year
later a contralateral breast cancer was discovered and treated
with radiation therapy. In October 1989 a solitary tum-our in
the right cerebellar hemisphere was removed. Microscopic
examination revealed a metastasis from breast cancer. Patient
characteristics are summarised in Table I.
Tamoxifen treatment
All patients received tamoxifen treatment during a period
immediately before surgical removal and collection of the
tissue specimens.
Patient AN received 30 mg daily for 1 week prior to
surgery. Patient BO was in steady state after treatment for 6
months with 50-mg tamoxifen daily. At the day of operation
she received only 30mg tamoxifen. Patient RA was given
60 mg tamoxifen for 3 days and then 30 mg daily for 4 days
prior to operation.
The tamoxifen doses are included in Table I.
Surgery and sample collection
All patients underwent a suboccipital craniotomy. Before
opening the dura, the subarachnoidal space was punctured,
and CSF was aspirated. The tumour was located intrapar-
enchymally in all three patients. To obtain access to the
tumour it was therefore necessary to remove apparently nor-
mal cerebellar tissue. Specimens from brain and tumour tis-
sue were collected.
Tumour and normal brain tissue obtained at surgery were
washed in saline to remove blood, immediately frozen and
stored at - 90'C until analysis. Serum and CSF obtained
during surgery were frozen and stored at - 90'C.
Determination oftamoxifen and its metabolites
Tissue specimens (metastatic tumour and normal brain tis-
sue) were thawed and then homogenised (1:5, w:v) at
20,000 rev min- ' in ice cold 50 mM Tris-HCI buffer, pH 7.4,
using an Ultra Turrax homogeniser.
Samples (0.6 ml) of tissue homogenate, serum and CSF
were mixed with an equal volume of acetonitrile, and the
precipitated protein removed by centrifugation (13,000 g for
5 min). The supernatants were transferred to sample vials,
capped and analysed by high-performance liquid chromato-
graphy (HPLC).
Tamoxifen, metabolites Y, B, BX, X and Z were deter-
mined in the acetonitrile extract from tissue, serum and CSF.
The method involves separation of these compounds by
reversed-phase low-dispersion liquid chromatography. The
analytes were converted to fluorophors by subjecting the
effluent from the column to ultra-violet illumination while
passing through a quartz tube. This method and recent
modifications have been published elsewhere (Lien et al.,
1989; Lien et al., 1987).
The detection limit of tamoxifen and its metabolites was
higher for tissues (about 5 ng g-') than for serum (1 ng ml-',
Lien et al., 1987), due to 6-fold dilution during tissue proces-
sing.
The identity of the analytes confirmed by liquid
chromatography/mass spectrometry (LC/MS), using an on-
line mass spectrometer (Model 201; Vestec, Houston, TX)
connected to the analytical column (Lien et al., 1988).
Results
Recovery and identification oftamoxifen and metabolites
Recovery experiments were done to evaluate the extraction
procedure, i.e. whether some compounds were trapped in the
pellet. To obtain this information, we spiked tissue
homogenate with amounts of drug that could be exactly
determined without interference from the detection limit of
the chromatographic procedure. We added tamoxifen and
metabolites Y, B, BX, X and Z dissolved in methanol to
homogenate of brain tissue obtained by autopsy from
patients not receiving tamoxifen. The final concentrations of
these compounds were 100ngml-l which resulted in a
methanol concentration of 0.I%. The homogenates were then
extracted with acetonitrile and processed as described in the
Material and methods section. The recovery of tamoxifen
and metabolites from tissue extract was higher than 93%,
and the coefficient of variation was below 2% for all com-
pounds.
Tamoxifen and its metabolites (Y, B, BX, X and Z, Figure
2) were identified in tissue extracts by comparing the reten-
tion times with those of authentic standards. In addition, the
identities were confirmed by determining the (M + 1)+ion
using LC/MS (Lien et al., 1988).
Multiple small fluorescence peaks eluted before tamoxifen
(Figure 2), corresponding to retention times between
9-13 min. One of these peaks (retention time of 13- 14 min)
coeluted with authentic metabolite BX whereas three peaks
eluting ahead of this peak had a (M + 1)+ion of 388. This is
identical to the (M + 1)+ion of metabolite B. One of these
peaks coeluted with metabolite B. The additional two peaks
may represent the cis-isomer of metabolite B and/or
metabolites of tamoxifen hydroxylated in another position
than position 4.
Chromatogramsfrom serum, CSFand tissue
Figure 2 shows the elution profiles for serum, CSF, brain
tissue and brain metastases. Solid tissue was diluted 6-fold
during homogenisation, and then extracted with an equal
volume of acetonitrile, whereas serum and CSF were ex-
tracted without prior dilution. The attenuation of the traces
in Figure 2 for serum and CSF were therefore reduced 1:6 to
allow comparison with the profiles for the solid tissues.
Tamoxifen and all the metabolites which we identified in
human serum, Y, B, BX, X and Z, could be demonstrated in
both brain tissue and brain metastases from all patients.
Material from the tissue samples eluting near the solvent
front interferred with the exact determination of metabolite
Y (retention time of 3.8 min). The other metabolites and
tamoxifen eluted as distinct peaks. In addition to the hy-
droxylated metabolites (Y, B and BX) two additional
fluorescence peaks with a (M + 1)+ion of 388 were detected
in specimens from metastases and brain. These were abund-
ant in brain metastases from all the patients. Notably, the
chromatographic profiles show a marked enrichment of
Table I Patient characteristics and drug treatment
Tamoxifen treatment
Daily Interval between last
Patient Age Duration dose dose and operation Other
initials (years) (days) (mg) (h) drugs
AN 46 7 30 28 Dexamethasone
BO 71 180 50o 4 Furosemide
RA 54 7 30b 27 Dexamethasone
aOnly 20 mg at the day of operation. "60 mg at the first 3 days.TAMOXIFEN AND METABOLITES IN BRAIN 643
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Figure 2 Chromatograms of extracts from cerebrospinal fluid,
serum, brain tissue, and brain metastases from the patient AN.
Samples were subjected to reversed-phase chromatography as
described in the text. Solid tissues were diluted 6-fold during
sample preparation. The attenuation of the traces for serum and
CSF were reduced 1:6 to allow comparison with the profiles for
the solid tissues. Y, metabolite Y; B, metabolite B; BX,
metabolite BX; Tam, tamoxifen; Z, metabolite Z; X, metabolite
X.
tamoxifen and all metabolites in brain metastases and brain
tissue relative to serum (Figure 2).
An HPLC trace for brain tissue obtained at surgery from a
patient not receiving tamoxifen, contained no peaks coch-
romatographing with tamoxifen or its metabolites (data not
shown).
Using our routine chromatographic procedure, we could
not detect tamoxifen or its metabolites in CSF (Figure 2). We
have earlier determined tamoxifen and metabolite X in CSF
by top-concentrating the analytes on the reversed-phase col-
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umn (Lien et al., 1989). The limited amounts of CSF did not
allow us to repeat this procedure.
Quantitative relations
Tamoxifen and the metabolites X and Z could be quantitated
from serum and tissue specimens from all patients. The
hydroxylated species, metabolites B and BX, were detected in
solid tissue from all patients, and in serum from patient BO.
Only patient BO had been treated with tamoxifen for a
sufficiently long time period (180 days) to reach steady state
of plasma drug level. She had higher brain concentrations of
hydroxylated metabolites (Y, B and BX) than the two other
patients. Her concentrations of tamoxifen and its
demethylated metabolites (X and Z) in brain tissue were
higher than in the brain metastases.
The tissue concentrations of metabolite Z were con-
siderably higher in patient BO than in patients AN and RA.
The quantities of tamoxifen and metabolites detected in
serum, brain, and brain metastases from patients AN, BO,
and RA are depicted in Figure 3. Notably, the amounts of
drug and metabolites were up to 46-fold higher in brain and
brain metastases compared with serum, and slightly higher
concentrations were found in the tumour than in brain tissue
in two of three patients. In both serum and the solid tissue
specimens, metabolite X was the most abundant species,
followed by tamoxifen, metabolite Z and the hydroxylated
metabolites, in that order. Thus, the ratios between the
amounts of tamoxifen and metabolites are similar in serum,
brain tissues and brain metastases (Figure 3).
Discussion
This is the first report on tamoxifen distribution into normal
brain tissue and brain metastases from breast cancer in man.
We found that the concentrations of tamoxifen and its
metabolites are up to 46-fold higher in brain tissue and brain
metastases compared with the concentrations in serum
(Figures 2 and 3). Similar results have been obtained with
spayed mice injected with '4C tamoxifen (Wilking et al., 1982)
and in rats bearing mammary carcinoma and injected with
the tamoxifen analogue "C toremifen (Kangas et al., 1989).
Patient BO Patient RA
Serum Brain Brain Serum Brain Brain Serum Brain train
tissue motastasis tissue metstasis tissue metastais
Figure 3 Distribution of tamoxifen and metabolites in serum, brain tissue, and brain metastases from breast cancer in the patients
AN, BO and RA.
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These findings raise two important questions: (1) What are
the mechanisms of antioestrogen entry into brain metastases
and the surrounding brain tissue? (2) What are the implica-
tions of these findings regarding the clinical use of tamoxifen
against brain metastases from breast cancer?
Tamoxifen is a low molecular weight and highly lipophilic
compound in the non-ionised form. The hydroxylated
metabolites are somewhat more hydrophilic. It was long held
that only lipid soluble, low molecular weight compounds
cross the blood brain barrier. The view still prevails that
these are physiochemical properties favouring distribution of
xenobiotics across the intact blood brain barrier (Dauplat et
al., 1987; Greig et al., 1987).
Imipramine, desimipramine and phenothiazines are drugs
with properties similar to those of tamoxifen, i.e. basic, lipid
soluble, highly protein-bound compounds with a large dis-
tribution volume. In the rat brain, levels of imipramin and
desimipramine reached concentrations 20-40-fold higher
than those measured in the serum (Dingell et al., 1964).
Similar findings were reported in a study of a patient suc-
cumbing from imipramin intoxication (Dingell et al., 1964)
and from human studies on phenothiazines (Lacoursiere et
al., 1976). Thus, the distribution of these psychotropic drugs
into the intact brain resembles that observed for tamoxifen in
the present study.
Drug uptake in brain metastases may differ from that in
normal brain tissue. There is recent evidence that water
soluble cytostatic agents are able to penetrate into metastatic
tumours located in the central nervous system (Rosner et al.,
1983a; Rosner et al., 1986; Rosner et al., 1983b). Vick et al.
(1977) suggested that the role of lipid solubility for the
distribution of drugs into brain metastases has been over-
emphasised. They hypothesised that neovascularisation
associated with tumour growth may circumvent the blood
brain barrier, allowing accumulation of drug in tumour and
diffusion into adjacent normal brain tissue.
We observed that the concentration of tamoxifen and more
hydrophilic metabolites may be even higher in tumour than
in normal brain tissue (Patients AN and RA, Figure 3) and
are abundant in these tissues relative to serum. The ratios
between concentrations of tamoxifen and metabolites, includ-
ing the water soluble hydroxylated species, were similar for
tumour, brain tissue and serum (Figure 3). These observa-
tions suggest that partition of lipophilic compounds into
brain lipids is not the only factor responsible for the distribu-
tion of tamoxifen and its metabolites into these solid tissues.
The high drug and metabolite levels in the metastatic
tumour may suggest association of these agents with tumour
constituents. The binding capacity of oestrogen receptors
which have been demonstrated in metastases from breast
cancer is too low to account for the tamoxifen uptake in the
tumour tissue. The presence of other acceptors for anti-
oestrogens has been reported. These include the so called anti-
oestrogen binding sites (which also bind phenothiazines),
cytochrome P-450, protein kinase C, calmodulin, histamin-
like receptors, muscarinic receptors and dopamine receptors
(Laziere et al., 1988; Weiss et al., 1988). Tamoxifen and its
metabolites may bind to these acceptors, but may also parti-
tion into the myelin layers of the brain.
Tamoxifen as well as metabolites B, BX and X have anti-
oestrogen properties. Their ability to compete with oestradiol
for the oestrogen receptor depends on the free concentrations
at the receptor site, and the relative binding affinities. We
calculated the total concentration of tamoxifen in brain
metastases to be about 3.5jM. This far exceeds the concen-
tration of oestradiol found in breast cancer tissue (about
1.3 nM) (Pasqualini et al., 1990). The affinity of B and BX
towards the oestrogen receptor exceed that of oestradiol,
whereas that of tamoxifen and metabolite X are about 50-
fold lower (Robertson et al., 1982). Although reservation
must be made because the free concentrations of ligands at
the receptor site are unknown, the amounts of tamoxifen and
its metabolites found in the metastases are probably pharma-
cologically significant.
Tamoxifen metabolites in brain and tumour may either be
formed in the liver and supplied via the circulation or formed
locally in the brain and/or tumour. N-Demethylation and
hydroxylation of xenobiotics, catalysed by mixed function
oxidases, have been demonstrated in brain (Ghersi-Egea et
al., 1987). However, our observation that the ratios between
tamoxifen and metabolite concentrations were similar in
brain, tumour and serum favours the possibility that the
metabolites present in these solid tissues are supplied from
the circulation.
Obviously, the therapeutic effect of tamoxifen against
metastatic tumour in the brain depends on the concentrations
of the cytotoxic agent(s) including active metabolites in the
cancer cells. Therefore, our observation that the contents of
both the parent drug and serum metabolites are high in
tumour, fulfils a prerequisite for antitumour effect in vivo.
The hydroxylated metabolites of tamoxifen found in serum
are present in relatively high concentrations in the brain
tumour (Figure 3). If the cytotoxicity and thereby the
anticancer effect are mediated through interaction with
oestrogen receptors, the presence of these metabolites may be
important since hydroxylated metabolites have higher affinity
towards the receptor than the parent drug, at least in vitro
(Robertson et al., 1982). However, tamoxifen also exerts
cytotoxic effects independent of oestrogen receptors (Biswas
et al., 1989; Brandes et al., 1986; Etienne et al., 1989; O'Brian
et al., 1988; Su et al., 1985; Tang et al., 1989). These may be
operating at the high concentrations of tamoxifen detected in
the metastatic brain tumour.
Recent investigations suggest that brain metastases re-
spond to chemotherapy (Ginsberg et al., 1981; Rosner et al.,
1986; Rosner et al., 1983b; Vlasveld et al., 1990) and tamoxi-
fen has been shown to be effective against brain metastases
from breast cancer (Carey et al., 1981; Colomer et al., 1988;
Hansen et al., 1986). Our finding that high concentrations of
tamoxifen and metabolites are obtained in brain metastases
from breast cancer, suggests that such tumours are not
localised in a sanctuary. Further trials on tamoxifen therapy
against breast cancer metastases are warranted.
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